Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Larry Brew who wrote (1245)	1/12/1999 11:55:00 AM
From: Andrew H	Respond to of 1510

Bottom line is there was no statistical significance for the trial. The FDA will NOT recommend a drug which showed no statistical significance overall. Now they can do a different trial with a new design and hope it will show significance--then they will have one trial without significance and hopefully one with. That will take a loooong time. If they can get a P3 with significance, that should make approval likely--however since they already have a 2B showing no significance, the FDA might want a second P3.